Successful oxaliplatin desensitization protocol in a patient with colorectal metastatic cancer.

Cindy E de Lira-QuezadaRosalaura V Villarreal GonzálezSandra N Gonzalez-DiazLigia L Carrasco-Diaz

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Approximately 50% of patients who are exposed to oxaliplatin may have hypersensitivity despite premedication. Desensitization protocol induces tolerance to a drug temporarily and is dependent on continuous exposure.

Keyphrases

end stage renal disease
randomized controlled trial
ejection fraction
newly diagnosed
chronic kidney disease
small cell lung cancer
prognostic factors
papillary thyroid
peritoneal dialysis
emergency department
drug induced
patient reported outcomes
young adults
patient reported